Pharmacokinetic Model of Drug Interaction of Tacrolimus with Combined Administration of CYP3A4 Inhibitors Voriconazole and Clarithromycin After Bone Marrow Transplantationdoi:10.1007/s13318-024-00915-2A pharmacokinetic model has been developed to quantify the drug鈥揹rug interactions of tacrolimus with ...
Many drugs that are CYP3A4 substrates, inhibitors, and inducers are also substrates, inhibitors, or inducers of the ABC transport protein known as P-glycoprotein. Many drug interactions, therefore, involve additive effects of both CYP3A4 and P-glycoprotein. Table CYP3A4 Substrates Producing Potenti...
Computational modeling of CYP3A4 inhibitors provided a suitable strategy to screen pharmaceutical grade compounds that may potentially inhibit presystemic CYP3A4-dependent drug metabolism with the prospect of improving oral drug bioavailability. 2012 Wiley Periodicals, Inc. and the American Pharmacists ...
Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability[J] . Pius Fasinu,Yahya E. Choonara,Riaz A. Khan,Lisa C. Du Toit,Pradeep Kumar,Valence M. K. Ndesendo,Viness Pillay.J. Pharm. Sci. . 2012 (2)...
Concomitant CYP3A4 inhibitors and calcium channel antagonist therapy is associated with an increased risk of adverse drug reactionsPublic HealthCalciumHigh RiskMultivariate AnalysisCalcium ChannelReactions Weekly -doi:10.2165/00128415-200811900-00012None
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transportersdoi:10.1124/dmd.115.067744Lydia Vermeer...
CP-029How to deal with a new drug interaction? example of the contraindication alfuzosin–strong CYP3A4 inhibitorsBackground Since 2014, the French Medicine Agency contraindicates alfuzosin with strong cytochrome P450 3A4 (CYP 3A4) inhibitors, but gives no information on how to manage it. We ...
The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo. Toxicol. In Vitro 2017, 40, 26-33. [CrossRef]Li M, de Graaf IA, van de Steeg E, de Jager MH, Groothuis GM (...
So far, these parameters were established for 21 substrates and 17 inhibitors. The goals of our study were to test the assumption of substrate independence of the potency of inhibitors in vivo and to estimate the CR and IR for an extended list of substrates and inhibitors of CYP3A4. The ...
Clinically significant drug-drug interactions between tramadol and CYP3A4 inhibitors: disproportionality analysis in VigiBase and hypothesis on the underlying mechanismEuropean Journal of Clinical Pharmacology -doi:10.1007/s00228-020-02881-5Springer Berlin Heidelberg...